SynthesisFrontiers in immunology2023

Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.

Xiao Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.